Chemoprevention for prostatic carcinoma: The role of flutamide in patients with prostatic intraepithelial neoplasia.
High-grade prostatic intraepithelial neoplasia (HGPIN) is believed to be a precursor for prostatic adenocarcinoma. The prevalence of prostatic intraepithelial neoplasia (PIN) increases with advancing age. Autopsy studies suggest that PIN may precede the development of prostatic adenocarcinoma by up to 10 years. As such, HGPIN is believed to be a marker of increased risk. This provides a potential opportunity for chemoprevention. Flutamide is 1 agent with potential activity and limited side effects that may act to prevent or delay the onset of prostatic adenocarcinoma in men with HGPIN. A clinical trial is currently underway to assess the efficacy of flutamide.
Alberts
S R
SR
Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA.
Blute
M L
ML
D000367:Age Factors; D000726:Androgen Antagonists / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D017322:Clinical Trials, Phase II as Topic; D004311:Double-Blind Method; D005485:Flutamide / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D011467:Prostate / Q000473:pathology; D019048:Prostatic Intraepithelial Neoplasia / Q000473:pathology / Q000517:prevention & control*; D011471:Prostatic Neoplasms / Q000473:pathology / Q000517:prevention & control*; D016032:Randomized Controlled Trials as Topic
D000726:Androgen Antagonists; D018931:Antineoplastic Agents, Hormonal; D005485:Flutamide